32993393|t|Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer.
32993393|a|OBJECTIVE: To assess the efficacy and safety of cetuximab (CE) versus bevacizumab (BE) maintenance treatment after prior 8-cycle modified 5-fluorouracil, folinate, oxaliplatin, and irinotecan (FOLFOXIRI) plus CE induction therapy in treatment-naive KRAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC). METHODS: From 2012 to 2017, prospectively maintained databases were reviewed to assess Asian postmenopausal women with treatment-naive KRAS and BRAF wt mCRC who underwent modified FOLFOXIRI plus CE induction therapy, followed by CE or BE maintenance until disease progression or death. Co-primary clinical endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS: A total of 222 women were included (CE n = 110 and BE n = 112). At a median follow-up of 27.0 months (interquartile range, 6.5-38.6 months), median PFS was 21.9 months (95% confidence interval [CI] 16.4-24.4) and 17.7 months (95% CI 11.3-19.0) for CE and BE groups, respectively (hazard ratio [HR] 0.31, 95% CI 0.15-0.46); median OS was 26.0 months (95% CI 23.4-28.7) and 22.7 months (95% CI 21.2-24.3) for CE and BE groups, respectively (HR 0.22, 95% CI 0.11-0.37). CONCLUSIONS: CE maintenance treatment is more poorly tolerated but has a slightly more modest survival benefit compared with BE maintenance treatment in mCRC.
32993393	0	9	Cetuximab	Chemical	MESH:D000068818
32993393	17	28	bevacizumab	Chemical	MESH:D000068258
32993393	74	83	FOLFOXIRI	Chemical	-
32993393	89	98	cetuximab	Chemical	MESH:D000068818
32993393	123	128	women	Species	9606
32993393	150	154	KRAS	Gene	3845
32993393	159	163	BRAF	Gene	673
32993393	174	202	metastatic colorectal cancer	Disease	MESH:D015179
32993393	252	261	cetuximab	Chemical	MESH:D000068818
32993393	274	285	bevacizumab	Chemical	MESH:D000068258
32993393	287	289	BE	Chemical	MESH:D000068258
32993393	342	395	5-fluorouracil, folinate, oxaliplatin, and irinotecan	Chemical	-
32993393	397	406	FOLFOXIRI	Chemical	-
32993393	453	457	KRAS	Gene	3845
32993393	462	466	BRAF	Gene	673
32993393	482	510	metastatic colorectal cancer	Disease	MESH:D015179
32993393	512	516	mCRC	Disease	MESH:D015179
32993393	627	632	women	Species	9606
32993393	654	658	KRAS	Gene	3845
32993393	663	667	BRAF	Gene	673
32993393	671	675	mCRC	Disease	MESH:D015179
32993393	699	708	FOLFOXIRI	Chemical	-
32993393	754	756	BE	Chemical	MESH:D000068258
32993393	775	782	disease	Disease	MESH:D004194
32993393	798	803	death	Disease	MESH:D003643
32993393	923	928	women	Species	9606
32993393	959	961	BE	Chemical	MESH:D000068258
32993393	1163	1165	BE	Chemical	MESH:D000068258
32993393	1322	1324	BE	Chemical	MESH:D000068258
32993393	1500	1502	BE	Chemical	MESH:D000068258
32993393	1528	1532	mCRC	Disease	MESH:D015179
32993393	Association	MESH:D015179	673
32993393	Comparison	MESH:D000068258	MESH:D000068818
32993393	Negative_Correlation	MESH:D000068818	MESH:D015179
32993393	Negative_Correlation	MESH:D000068258	MESH:D015179
32993393	Association	MESH:D015179	3845

